Intellia therapeutics revenue
Nettet8. nov. 2024 · Intellia Therapeutics ( NASDAQ:NTLA) Third Quarter 2024 Results Key Financial Results Revenue: US$13.3m (up 84% from 3Q 2024). Net loss: US$113.2m … Nettet13. apr. 2024 · 1. Intellia Therapeutics. Gene-editing specialist Intellia Therapeutics has admittedly been a stress-inducing investment over the past year as its share price is down about 45%. The company generated $52 million in revenue last year but it incurred a net loss of $474 million.
Intellia therapeutics revenue
Did you know?
Nettet5. mai 2024 · Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -76.58% and 8.80%, respectively, for the quarter ended March 2024. NettetIntellia Therapeutics, Inc. Healthcare Biotechnology USA statements Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics.
Nettet3. nov. 2024 · Intellia Therapeutics, Inc. , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $13.27 million for the quarter … Nettet14. apr. 2024 · Intellia Therapeutics shares last traded at $35.16, with a volume of 86,959 shares trading hands. ... The firm’s quarterly revenue was up 5.4% on a year-over-year basis.
Nettet13. apr. 2024 · Intellia Therapeutics Inc. (NASDAQ:NTLA) shares, rose in value on Thursday, ... Wall Street analysts also predicted that in 2024, the company’s y-o-y revenues would reach $49.6 million, representing a decrease of -4.80% from the revenues reported in the last year’s results. Nettet14. apr. 2024 · Intellia Therapeutics shares last traded at $35.16, with a volume of 86,959 shares changing hands. ... The business’s revenue was up 5.4% compared to the same quarter last year.
NettetIntellia Therapeutics Inc. Watch list Create NTLA Alert After Hours Last Updated: Mar 1, 2024 7:57 p.m. EST Delayed quote $ 40.50 -0.25 -0.61% After Hours Volume: 15.37K Advanced Charting Volume:...
Nettet6. mai 2016 · Intellia Therapeutics's valuation in September 2015 was $274.68M. Intellia Therapeutics's latest post-money valuation is from May 2016. Sign up for a free trial to see Intellia Therapeutics's valuations in May 2016, November 2014 and more. Intellia Therapeutics's 2015 revenue was $6.04M. Intellia Therapeutics's most recent … paris gallery near meNettet4. nov. 2024 · INTELLIA THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Amounts in thousands, except per share data) Three Months Ended September 30, Nine Months Ended September 30, 2024 2024 2024 … times zones in australiaNettet28. jul. 2024 · As of Q121, Intellia reported a cash position of $995m, down from $1.1bn in Q121. The company earned $11.3m of collaboration revenues in Q121, and made a net loss of $147m. Net loss in FY21 was... timet 100 titanium wayNettet12 timer siden · Two stocks that analysts appear to be bullish on right now are Intellia Therapeutics (NTLA-2.79%) and Rivian Automotive ... Last year, Rivian reported $1.7 billion in revenue, ... paris gand trainNettet5. mai 2024 · Intellia Therapeutics, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $11.25 million for the quarter ended March 2024, surpassing the Zacks... times zones national geographicNettet6. aug. 2024 · Intellia Therapeutics, Inc. ... Biomedical and Genetics industry, posted revenues of $16.26 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 72.13%. times zones in russiaNettet24. feb. 2024 · Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress - On track to present additional ... March 7, 2024. Intellia ... Collaboration Revenue: Collaboration revenue increased by $6.3 million to $12.9 million during the fourth quarter of 2024, ... time table 100